Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Participant Engagement and Adherence to Providing Smartwatch and Patient-Reported Outcome Data: Digital Tracking of Rheumatoid Arthritis Longitudinally (DIGITAL) Real-World Study

View through CrossRef
Background Digital health studies using electronic patient-reported outcomes (ePROs) and wearables bring new challenges, including the need for participants to consistently provide trial data. Objective This study aims to characterize the engagement, protocol adherence, and data completeness among participants with rheumatoid arthritis enrolled in the Digital Tracking of Arthritis Longitudinally (DIGITAL) study. Methods Participants were invited to participate in this app-based study, which included a 14-day run-in and an 84-day main study. In the run-in period, data were collected via the ArthritisPower mobile app to increase app familiarity and identify the individuals who were motivated to participate. Successful completers of the run-in period were mailed a wearable smartwatch, and automated and manual prompts were sent to participants, reminding them to complete app input or regularly wear and synchronize devices, respectively, during the main study. Study coordinators monitored participant data and contacted participants via email, SMS text messaging, and phone to resolve adherence issues per a priori rules, in which consecutive spans of missing data triggered participant contact. Adherence to data collection during the main study period was defined as providing requested data for >70% of 84 days (daily ePRO, ≥80% daily smartwatch data) or at least 9 of 12 weeks (weekly ePRO). Results Of the 470 participants expressing initial interest, 278 (59.1%) completed the run-in period and qualified for the main study. Over the 12-week main study period, 87.4% (243/278) of participants met the definition of adherence to protocol-specified data collection for weekly ePRO, and 57.2% (159/278) did so for daily ePRO. For smartwatch data, 81.7% (227/278) of the participants adhered to the protocol-specified data collection. In total, 52.9% (147/278) of the participants met composite adherence. Conclusions Compared with other digital health rheumatoid arthritis studies, a short run-in period appears useful for identifying participants likely to engage in a study that collects data via a mobile app and wearables and gives participants time to acclimate to study requirements. Automated or manual prompts (ie, “It’s time to sync your smartwatch”) may be necessary to optimize adherence. Adherence varies by data collection type (eg, ePRO vs smartwatch data). International Registered Report Identifier (IRRID) RR2-10.2196/14665
Title: Participant Engagement and Adherence to Providing Smartwatch and Patient-Reported Outcome Data: Digital Tracking of Rheumatoid Arthritis Longitudinally (DIGITAL) Real-World Study
Description:
Background Digital health studies using electronic patient-reported outcomes (ePROs) and wearables bring new challenges, including the need for participants to consistently provide trial data.
Objective This study aims to characterize the engagement, protocol adherence, and data completeness among participants with rheumatoid arthritis enrolled in the Digital Tracking of Arthritis Longitudinally (DIGITAL) study.
Methods Participants were invited to participate in this app-based study, which included a 14-day run-in and an 84-day main study.
In the run-in period, data were collected via the ArthritisPower mobile app to increase app familiarity and identify the individuals who were motivated to participate.
Successful completers of the run-in period were mailed a wearable smartwatch, and automated and manual prompts were sent to participants, reminding them to complete app input or regularly wear and synchronize devices, respectively, during the main study.
Study coordinators monitored participant data and contacted participants via email, SMS text messaging, and phone to resolve adherence issues per a priori rules, in which consecutive spans of missing data triggered participant contact.
Adherence to data collection during the main study period was defined as providing requested data for >70% of 84 days (daily ePRO, ≥80% daily smartwatch data) or at least 9 of 12 weeks (weekly ePRO).
Results Of the 470 participants expressing initial interest, 278 (59.
1%) completed the run-in period and qualified for the main study.
Over the 12-week main study period, 87.
4% (243/278) of participants met the definition of adherence to protocol-specified data collection for weekly ePRO, and 57.
2% (159/278) did so for daily ePRO.
For smartwatch data, 81.
7% (227/278) of the participants adhered to the protocol-specified data collection.
In total, 52.
9% (147/278) of the participants met composite adherence.
Conclusions Compared with other digital health rheumatoid arthritis studies, a short run-in period appears useful for identifying participants likely to engage in a study that collects data via a mobile app and wearables and gives participants time to acclimate to study requirements.
Automated or manual prompts (ie, “It’s time to sync your smartwatch”) may be necessary to optimize adherence.
Adherence varies by data collection type (eg, ePRO vs smartwatch data).
International Registered Report Identifier (IRRID) RR2-10.
2196/14665.

Related Results

Hubungan Rheumatoid Arthritis dengan Kejadian Insomnia pada Usia Lanjut
Hubungan Rheumatoid Arthritis dengan Kejadian Insomnia pada Usia Lanjut
One of the health problems often experienced by the elderly is rheumatoid arthritis. Joint disorders experienced by people with rheumatoid arthritis will have an impact on physical...
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash Abstract This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
Impact of seropositivity and disease-modifying antirheumatic drugs on pulmonary tuberculosis risk in rheumatoid arthritis
Impact of seropositivity and disease-modifying antirheumatic drugs on pulmonary tuberculosis risk in rheumatoid arthritis
BackgroundIt remains unclear whether active pulmonary tuberculosis risk is still high in rheumatoid arthritis patients in settings where tuberculosis infection screening is perform...
THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION
THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION
The followina are abstracts of papers presented at the 35th Annual Scientific Meeting of the Australian Rheumatology Association, held in Perth, Western Australia, 1–4 December. 19...
THE COMBINED AUSTRALIAN AND NEW ZEALAND RHEUMATOLOGY ASSOCIATIONS
THE COMBINED AUSTRALIAN AND NEW ZEALAND RHEUMATOLOGY ASSOCIATIONS
CYTOKINES IN SLE: LESSONS FROM EXPERIMENTAL MODELS AND MAN, Michael J Elliott*., Peter Charles, Ravinder N MainiTHE FAS GENE IN HUMAN LUPUS: THE EXPRESSION OF VARIANT TRANSCRIPTS.,...

Back to Top